Skip to content Skip to footer
VIEWPOINTS_Avery Ince_2023

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Shots: Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023 The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]